🇺🇸 Incresync in United States

44 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Malaise — 9 reports (20.45%)
  2. Bladder Spasm — 7 reports (15.91%)
  3. Lactic Acidosis — 7 reports (15.91%)
  4. Pyrexia — 7 reports (15.91%)
  5. Rectal Tenesmus — 7 reports (15.91%)
  6. Drug Reaction With Eosinophilia And Systemic Symptoms — 2 reports (4.55%)
  7. Hypoglycaemia — 2 reports (4.55%)
  8. Abdominal Pain — 1 report (2.27%)
  9. Abdominal Pain Upper — 1 report (2.27%)
  10. Amylase Increased — 1 report (2.27%)

Source database →

Incresync in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Incresync approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Incresync in United States?

University Medical Centre Ljubljana is the originator. The local marketing authorisation holder may differ — check the official source linked above.